Nippon Shinyaku
Aug 20, 2024
In Search for a Curative Treatment Option for Duchenne Muscular Dystrophy
Sarepta Therapeutics, a leader in precision genetic medicine for rare diseases, has recently achieved a significant milestone with the FDA's approval of AMONDYS 45 (casimersen). This antisense oligonucleotide, developed from Sarepta’s phosphorodiamidate morpholino oligomer (PMO) platform, is now approved for treati...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
